Arm A for COVID-19

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of California Irvine Medical Center, Orange, CA
COVID-19
NAC (N-acetyl cysteine) , Alpha lipoic acid (ALA), liposomal glutathione (GSH) - DietarySupplement
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be randomized in to one of two groups. Depending on the group they are randomized in to, subjects will be taking either a combination of NAC, Alamax CR, and liposomal GSH or the same three nutritional supplements with a multivitamin and magnesium. Regardless of the group, subjects will be asked questions to assess their COVID symptoms, physical and mental health status. They will also be asked to take blood samples.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: Will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy

Month 2
Change in Time to Clinical Recovery (TTCR)
Month 2
COVID Severity of Symptoms Questionnaire
Month 4
Assess Changes in Symptoms of Post-Acute Sequelae of COVID (PASC)
Month 4
Change in Quality of Life Using SF-36 Survey

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Arm B
1 of 2
Arm A
1 of 2
Active Control
Experimental Treatment

50 Total Participants · 2 Treatment Groups

Primary Treatment: Arm A · No Placebo Group · Phase < 1

Arm A
DietarySupplement
Experimental Group · 1 Intervention: NAC (N-acetyl cysteine) , Alpha lipoic acid (ALA), liposomal glutathione (GSH) · Intervention Types: DietarySupplement
Arm B
DietarySupplement
ActiveComparator Group · 1 Intervention: NAC (N-acetyl cysteine) , Alpha lipoic acid (ALA), liposomal glutathione (GSH) · Intervention Types: DietarySupplement

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy

Trial Background

Alpesh N Amin, Principal Investigator
Principal Investigator
University of California, Irvine
Closest Location: University of California Irvine Medical Center · Orange, CA
Photo of Orange  1Photo of Orange  2Photo of Orange  3
2006First Recorded Clinical Trial
3 TrialsResearching COVID-19
42 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.